Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2021 2
2023 2
2024 10
2025 30
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.
Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Pinkerton JV, et al. JAMA. 2024 Aug 22;332(16):1343-54. doi: 10.1001/jama.2024.14618. Online ahead of print. JAMA. 2024. PMID: 39172446 Free PMC article.
OBJECTIVE: To evaluate the efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist, for the treatment of moderate to severe menopausal vasomotor symptoms. ...Elinzanetant improved sleep disturbances and menopause-related quality of life a …
OBJECTIVE: To evaluate the efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist, for the treatment of …
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.
Cardoso F, Parke S, Brennan DJ, Briggs P, Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L. Cardoso F, et al. N Engl J Med. 2025 Aug 21;393(8):753-763. doi: 10.1056/NEJMoa2415566. Epub 2025 Jun 2. N Engl J Med. 2025. PMID: 40454634 Clinical Trial.
Women were randomly assigned in a 2:1 ratio to receive once-daily elinzanetant at a dose of 120 mg for 52 weeks or once-daily placebo for 12 weeks followed by once-daily elinzanetant at a dose of 120 mg for 40 weeks. ...RESULTS: A total of 316 participants were assi …
Women were randomly assigned in a 2:1 ratio to receive once-daily elinzanetant at a dose of 120 mg for 52 weeks or once-daily placebo …
Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.
Menegaz de Almeida A, Oliveira P, Lopes L, Leite M, Morbach V, Alves Kelly F, Barros Í, Aquino de Moraes FC, Prevedello A. Menegaz de Almeida A, et al. Obstet Gynecol. 2025 Mar 1;145(3):253-261. doi: 10.1097/AOG.0000000000005812. Epub 2025 Jan 2. Obstet Gynecol. 2025. PMID: 39746208
The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor symptoms, and menopause. METHODS OF STUDY SELECTION: Only RCTs comparing fezolinetant and elinzanetant with placebo for vasomotor symptom …
The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor symp …
Elinzanetant.
Hoofnagle JH. Hoofnagle JH. 2025 Dec 20. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2025 Dec 20. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 41570166 Free Books & Documents. Review.
Elinzanetant is an orally available neurokinin 1 and 3 receptor antagonist that is used to treat women with vasomotor symptoms (such as hot flashes) due to menopause. Elinzanetant is associated with a low rate of serum aminotransferase elevations during therapy but …
Elinzanetant is an orally available neurokinin 1 and 3 receptor antagonist that is used to treat women with vasomotor symptoms (such …
Elinzanetant: First Approval.
Lee A. Lee A. Drugs. 2026 Jan;86(1):121-125. doi: 10.1007/s40265-025-02244-3. Epub 2025 Nov 12. Drugs. 2026. PMID: 41222830 Free PMC article. Review.
Elinzanetant (Lynkuet ) is a non-hormonal, small-molecule neurokinin 1 (NK(1)) and 3 (NK(3)) antagonist being developed by Bayer for the treatment of vasomotor symptoms (VMS), which received its first approval in the UK in July 2025. ...This article summarizes the mileston …
Elinzanetant (Lynkuet ) is a non-hormonal, small-molecule neurokinin 1 (NK(1)) and 3 (NK(3)) antagonist being developed by Bayer for …
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
Panay N, Joffe H, Maki PM, Nappi RE, Pinkerton JV, Simon JA, Soares CN, Thurston RC, Francuski M, Caetano C, Genga K, Haberland C, Haseli Mashhadi N, Laapas K, Parke S, Seitz C, Schwarz J, Zuurman L. Panay N, et al. JAMA Intern Med. 2025 Nov 1;185(11):1319-1327. doi: 10.1001/jamainternmed.2025.4421. JAMA Intern Med. 2025. PMID: 40920404 Free PMC article. Clinical Trial.
At week 12, the mean change from baseline in daily moderate to severe VMS frequency was -5.4 (95% CI, -6.3 to -4.5) for elinzanetant and -3.5 (95% CI, -4.1 to -2.9) for placebo; the least-squares mean difference for elinzanetant vs placebo was -1.6 (95% CI, -2.0 to …
At week 12, the mean change from baseline in daily moderate to severe VMS frequency was -5.4 (95% CI, -6.3 to -4.5) for elinzanetant …
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?
Doggrell SA. Doggrell SA. Expert Opin Pharmacother. 2025 Mar;26(4):349-354. doi: 10.1080/14656566.2025.2465875. Epub 2025 Feb 15. Expert Opin Pharmacother. 2025. PMID: 39927400 Review.
AREA COVERED: A combination of OASIS 1 and 2 in the menopause showed that elinzanetant caused a reduction in the frequency and intensity of VSM and may also independently reduce sleep disturbances. Adverse effects were low with elinzanetant. EXPERT OPINION: Further …
AREA COVERED: A combination of OASIS 1 and 2 in the menopause showed that elinzanetant caused a reduction in the frequency and intens …
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Simon JA, et al. Menopause. 2023 Mar 1;30(3):239-246. doi: 10.1097/GME.0000000000002138. Epub 2023 Jan 30. Menopause. 2023. PMID: 36720081 Free PMC article. Clinical Trial.

Least square mean reductions were statistically significant versus placebo at both primary endpoint time points for elinzanetant 120 mg (week 4: -3.93 [SE, 1.02], P < 0.001; week 12: -2.95 [1.15], P = 0.01) and at week 4 for elinzanetant 160 mg (-2.63 [1.03]; P =

…
Least square mean reductions were statistically significant versus placebo at both primary endpoint time points for elinzanetant 120 …
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms.
Hager M, Goldstein T, Fitz V, Ott J. Hager M, et al. Expert Opin Pharmacother. 2024 May;25(7):783-789. doi: 10.1080/14656566.2024.2358131. Epub 2024 Jun 13. Expert Opin Pharmacother. 2024. PMID: 38869992 Free article. Review.
Elinzanetant's reported peak drug concentrations are reached within one hour and the terminal elimination half-life is approximately 15 hours. ...Thus, 120 mg oral Elinzanetant/day was used in phase III trials, whose results have not yet been published....
Elinzanetant's reported peak drug concentrations are reached within one hour and the terminal elimination half-life is approximately …
Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women.
Pawsey S, Mills EG, Ballantyne E, Donaldson K, Kerr M, Trower M, Dhillo WS. Pawsey S, et al. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234. doi: 10.1210/clinem/dgab108. J Clin Endocrinol Metab. 2021. PMID: 33624806 Free PMC article. Clinical Trial.
Elinzanetant 120 mg prolonged the cycle length by median of 7.0 days (P = .023). Elinzanetant reduced the proportion of women with a luteal-phase serum progesterone concentration greater than 30 nmol/L (a concentration consistent with ovulation) in a dose-related ma …
Elinzanetant 120 mg prolonged the cycle length by median of 7.0 days (P = .023). Elinzanetant reduced the proportion of women …
48 results